行情

CFRX

CFRX

ContraFect
NASDAQ

实时行情|Nasdaq Last Sale

0.4300
+0.0968
+29.05%
盘后: 0.4400 +0.01 +2.33% 17:19 12/13 EST
开盘
0.3300
昨收
0.3332
最高
0.4800
最低
0.3213
成交量
296.94万
成交额
--
52周最高
2.180
52周最低
0.2693
市值
3,414.61万
市盈率(TTM)
9.77
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CFRX 新闻

  • 美国众议院司法委员会投票通过特朗普弹劾指控
  • 新浪财经.2小时前
  • 英国豪车制造商阿斯顿马丁与投资者会谈 评估融资
  • 新浪美股.3小时前
  • 美石油钻井数增加4座 结束连降但16周内已减少107座
  • FX168.4小时前
  • 保守党赢得1987年来最大胜利 欧股与英镑比翼齐飞
  • FX168.4小时前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
-0.08%

热门股票

名称
价格
涨跌幅

CFRX 简况

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
展开

Webull提供ContraFect Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。